NASDAQ:WVE Wave Life Sciences - WVE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $5.15 -0.05 (-0.96%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$5.05▼$5.3350-Day Range$3.61▼$7.0052-Week Range$1.16▼$7.12Volume337,960 shsAverage Volume483,804 shsMarket Capitalization$447.54 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Wave Life Sciences MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside29.4% Upside$6.67 Price TargetShort InterestHealthy1.76% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.01) to ($1.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector196th out of 1,028 stocksPharmaceutical Preparations Industry89th out of 501 stocks 3.2 Analyst's Opinion Consensus RatingWave Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.67, Wave Life Sciences has a forecasted upside of 29.4% from its current price of $5.15.Amount of Analyst CoverageWave Life Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.76% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Wave Life Sciences has recently increased by 2.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreWave Life Sciences has received a 74.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Wave Life Sciences is -0.75. Previous Next 2.1 News and Social Media Coverage News SentimentWave Life Sciences has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders32.20% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.18% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Wave Life Sciences are expected to grow in the coming year, from ($2.01) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWave Life Sciences has a P/B Ratio of 9.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Wave Life Sciences (NASDAQ:WVE) StockWave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.Read More Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address WVE Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comSVB Leerink Weighs in on Wave Life Sciences Ltd.'s Q1 2023 Earnings (NASDAQ:WVE)January 25, 2023 | finance.yahoo.comWave Life Sciences (NASDAQ:WVE) shareholders have earned a 115% return over the last yearFebruary 4, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 15, 2023 | reuters.comWVE.A - | Stock Price & Latest News | ReutersJanuary 13, 2023 | finance.yahoo.comMorphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?December 30, 2022 | msn.comAll You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to BuyDecember 21, 2022 | finanznachrichten.deWave Life Sciences USA, Inc.: Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular DystrophyDecember 19, 2022 | finance.yahoo.comWave Life Sciences Touts Encouraging Data From Duchenne Muscular Dystrophy StudyFebruary 4, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 19, 2022 | finance.yahoo.comWave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular DystrophyDecember 15, 2022 | finance.yahoo.comWave Life Sciences (WVE) Up 26% on Collaboration With GSKDecember 15, 2022 | finance.yahoo.comWave Life Sciences Ltd.'s (NASDAQ:WVE) Intrinsic Value Is Potentially 52% Above Its Share PriceDecember 13, 2022 | msn.comWave Life stock surges 20% in team up with GSK for genetic diseasesDecember 13, 2022 | finance.yahoo.comWave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic TargetsNovember 11, 2022 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Wave Life Sciences (WVE)November 10, 2022 | finanznachrichten.deWave Life Sciences USA, Inc.: Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 10, 2022 | technews.tmcnet.comWave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 10, 2022 | seekingalpha.comWave Life Sciences Ltd. (WVE) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comWave Life Sciences to Present at the Stifel 2022 Healthcare ConferenceNovember 3, 2022 | finance.yahoo.comWave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022October 12, 2022 | finance.yahoo.comIs Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?October 12, 2022 | finance.yahoo.comAtlas-backed gene-silencing startup winds downOctober 3, 2022 | finance.yahoo.comWave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific CongressesOctober 1, 2022 | seekingalpha.comWVE Wave Life Sciences Ltd.September 28, 2022 | finance.yahoo.comWave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor EventSeptember 27, 2022 | finance.yahoo.comWave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines ConferenceSeptember 23, 2022 | nasdaq.comInvestors in Wave Life Sciences (NASDAQ:WVE) from five years ago are still down 82%, even after 17% gain this past weekSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address WVE Company Calendar Last Earnings11/10/2022Today2/04/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:WVE CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees235Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.67 High Stock Price Forecast$8.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+29.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-122,250,000.00 Net Margins-3,662.25% Pretax Margin-3,667.14% Return on Equity-1,038.84% Return on Assets-79.51% Debt Debt-to-Equity RatioN/A Current Ratio2.05 Quick Ratio2.05 Sales & Book Value Annual Sales$40.96 million Price / Sales10.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book9.36Miscellaneous Outstanding Shares86,900,000Free Float58,919,000Market Cap$447.54 million OptionableOptionable Beta-0.96 Key ExecutivesPaul B. BolnoPresident, Chief Executive Officer & DirectorKyle MoranChief Financial & Accounting OfficerChandra VargeeseChief Technology OfficerChristopher FrancisSVP-Corporate Development & Head-Emerging AreasAnne-Marie Li-Kwai-CheungChief Development OfficerKey CompetitorsDesign TherapeuticsNASDAQ:DSGNEagle PharmaceuticalsNASDAQ:EGRXCOMPASS PathwaysNASDAQ:CMPSArbutus BiopharmaNASDAQ:ABUSVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 4,500 shares on 2/2/2023Ownership: 0.000%DekaBank Deutsche GirozentraleBought 35,000 shares on 2/1/2023Ownership: 0.040%Matisse CapitalBought 12,213 shares on 1/24/2023Ownership: 0.014%Matisse CapitalBought 12,213 shares on 1/20/2023Ownership: 0.014%Bank of New York Mellon CorpSold 3,705 shares on 12/8/2022Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions WVE Stock - Frequently Asked Questions Should I buy or sell Wave Life Sciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WVE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WVE, but not buy additional shares or sell existing shares. View WVE analyst ratings or view top-rated stocks. What is Wave Life Sciences' stock price forecast for 2023? 3 analysts have issued 1 year target prices for Wave Life Sciences' shares. Their WVE share price forecasts range from $5.00 to $8.00. On average, they expect the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price. View analysts price targets for WVE or view top-rated stocks among Wall Street analysts. How have WVE shares performed in 2023? Wave Life Sciences' stock was trading at $7.00 at the beginning of the year. Since then, WVE shares have decreased by 26.4% and is now trading at $5.15. View the best growth stocks for 2023 here. When is Wave Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our WVE earnings forecast. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.06. The firm had revenue of $0.29 million for the quarter, compared to analysts' expectations of $5.48 million. Wave Life Sciences had a negative net margin of 3,662.25% and a negative trailing twelve-month return on equity of 1,038.84%. What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO? 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN). What is Wave Life Sciences' stock symbol? Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE." Who are Wave Life Sciences' major shareholders? Wave Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DekaBank Deutsche Girozentrale (0.04%), Matisse Capital (0.01%), Matisse Capital (0.01%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Michael A Panzara, Paul Bolno and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Wave Life Sciences' stock price today? One share of WVE stock can currently be purchased for approximately $5.15. How much money does Wave Life Sciences make? Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $447.54 million and generates $40.96 million in revenue each year. The company earns $-122,250,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. How many employees does Wave Life Sciences have? The company employs 235 workers across the globe. How can I contact Wave Life Sciences? Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901. This page (NASDAQ:WVE) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.